Research Grade Coltuximab
Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ∼3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4.
Product Specifications
Product Name Alternative
SAR3419, CAS: 1269764-99-9
Accession Number
P15391
Expression System
Mammalian Cells
Reactivity
Human
Applications
Research Grade Biosimilar
Stability
Endotoxin
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Form
Liquid
Buffer
0.01M PBS, pH 7.4.
Notes
For research use only. Not suitable for clinical or therapeutic use.
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
